Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a probiotic cream soothe your Child's eczema?

NCT ID NCT07072273

Symptom relief Sponsor: Biogaia New Sciences AB Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a special moisturizing cream containing a friendly bacteria called Lactobacillus reuteri to see if it could improve eczema symptoms in children. Forty children aged 6 months to 12 years with mild-to-moderate eczema used the cream for 8 weeks. Researchers measured changes in eczema severity using a standard scoring system.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

40 people

The number who actually took part.

Started

Nov 2025

Finished

Apr 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

6 months to 12 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Pediatric patients of both sexes, aged between 6 months and 12 years, with a confirmed diagnosis of AD based on Hanifin and Rajka criteria (ANNEX VIII). SCORAD index between 20 and 50, inclusive. Signed informed consent by parents or legal guardians. Exclusion Criteria: History of phototherapy for the treatment of AD. Previous treatment with biologic agents or JAK inhibitors for AD. Use of systemic corticosteroids within one month prior to inclusion in the clinical trial. Use of topical corticosteroids within one month prior to inclusion in the clinical trial. Use of conventional systemic immunosuppressants for AD (e.g., azathioprine, methotrexate, or cyclosporine) within three months prior to inclusion in the clinical trial. Use of oral or topical probiotics within two months prior to inclusion in the clinical trial. Use of topical or systemic antibiotics within one month prior to inclusion in the clinical trial. Known hypersensitivity to the investigational product or any of its components. Underlying immune-mediated diseases requiring systemic corticosteroid therapy. Active infection in areas affected by AD requiring antibiotic, antifungal, or antiviral treatment within the one month prior to inclusion in the clinical trial. Fever at the start of treatment (axillary temperature \>37.5 °C or equivalent). Diagnosed immunodeficiency disorders. Current or past diagnosis of malignant neoplasms. Any concurrent dermatologic or medical condition that, in the investigator's opinion, could interfere with the subject's response to treatment or require continuous use of topical corticosteroids. Participation in other clinical research studies involving investigational products within one month prior to inclusion in the clinical trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atopic dermatitis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema Eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atopic dermatitis

Contacts and locations

Locations

  • Belaneve Clinics

    Alicante, Spain

  • Centro Dermatológico Estético Alicante

    Alicante, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.